Tango Therapeutics, Inc.TNGXNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank67
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-168.40%
↑ 45% vs avg
Percentile
P67
Within normal range
Streak
1 yr
Consecutive growthExpanding
Average
-303.72%
Historical baseline
PeriodValueYoY Change
TTM-168.40%+50.5%
2024-340.15%-11.2%
2023-305.96%+30.5%
2022-440.32%-184.7%
2021-154.67%+76.5%
2020-657.61%-1016.4%
2019-58.90%-